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The genomic era has introduced concepts of “personalized medicine” and “targeted ther-
apy” in the field of oncology. Medicine has become increasingly complex with a plethora of
potential dilemmas in diagnosis, treatment, and management. The focus on classical out-
comes for clinical decision-making is now increasingly being replaced by patient-reported
outcome measures (PROMs). PROMs should increasingly now be in the center of patient-
centered decision-making, based on valid, reliable, and clinically useful measures delivered
directly by the patient to the caregiver. Surgeons’ ability to interpret and apply PROMs and
quality of life results must improve by education and further research, and has an unreleased
potential to contribute to a better understanding of the patients’ well-being. A number of
caveats must be addressed before this can be brought to fruition; standardization for valid
items; appropriate use of instruments; correct timing of the application; missing data han-
dling, compliance, and respondent drop-outs are but a few issues to be addressed. Based
on the apparent lack of use in both research and clinical work, it should call for an educational
effort to address this among surgeons caring for patients with cancer.
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INTRODUCTION
The genomic era has swept the medical community since the
beginning of the twenty-first century, leading to an advent of “per-
sonalized medicine” and “targeted therapy” in particular within
the field of oncology. The opportunities are increasing together
with the survival rates, as are the cost of care. The outcome mea-
sures of the past, usually measured as hard endpoints in mortality
and morbidity (“M&M”), are no longer as valid as they used to
be. That is – while “M&M” should still be at their lowest possible
rates – traditional“M&M”are no longer viewed as a complete mea-
sure of “success” of any given treatment alone, such as evaluation
of outcomes for surgery for cancer. Rather, the patient-reported
outcomes should have an increased role in decision-making, but
must be based on valid, reliable, and clinically useful measures
(Lipscomb et al., 2007).
Indeed, medicine has become increasingly complex and with
complexity a plethora of choices and potential dilemmas in diag-
nosis, treatment, and management of disease – for both doctor
as well as the patient. With increasing knowledge and available
options, uncertainty may prevail over confidence and commu-
nication and interaction in the patient-doctor relationship may
suffer (Srivastava, 2011). Critical appraisal of the potential ben-
efits and harms of the given options, within the context of
the patient’s characteristics, conditions, and preferences has thus
become increasingly important. The “new-kid-on-the-block” in
research methodology is the approach to “patient-centered out-
comes” or “patient-reported outcomes” in the managed care for
patients – used as determinant of improvement of care and areas
for directed attention of care. As a form of practice, it seeks to
focus medical attention on the individual patient’s needs and
concerns, rather than the doctor’s (Bardes, 2012). The growing
demands for quality and safety in health care have refocused atten-
tion on patient outcomes(Lipscomb et al., 2007; Sloan et al., 2007;
Trotti et al., 2007; Wagner et al., 2007; Blazeby, 2010; Williamson
et al., 2012a; Macefield et al., 2013). This perspectives article
will briefly discuss the rationale; the definitions and perceived
concepts; the need for standards; issues related to surgical oncol-
ogy; and, eventually, some future directions for patient-centered
outcomes measures in health research.
THE RATIONALE: PATIENT-CENTERED OUTCOMES AS BASIS
FOR IMPROVED CARE
Several arguments are available for the need to embark on PCO
research (Gabriel and Normand, 2012). For one, the growing
and aging population present with increasingly complex med-
ical health problems. The primary disease under treatment may
not be the only disease needed to take into consideration, but
also other comorbid conditions that may be influenced by the
choice of treatment. As such, the need for integrating knowledge
about PCO in the discussion with patients becomes instrumen-
tal. Second, the available treatment options have increased both
in types and forms, with different effects and potential side-
effects for drugs or interventions aimed at the same disease. Thus,
weighing the benefits and risks for each individual should take
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into account the preferred knowledge about expected patient-
oriented outcomes. Third, the requirements to cost-effectiveness,
resource use, and priority in different health systems require an
explicit knowledge on how exactly the health systems require-
ment influence care on the patient level. Finally, the individ-
ualized approach to modern medicine with targeted therapies
based on a person’s genetic and epigenetic profile comes along
with the need to know how certain other patient’s characteris-
tics may influence the response and outcome of specific ther-
apies on a individual level rather than a group level. Each of
these points requires the development of a rigorous method-
ology in order to arrive at valid and reliable answers. While
this methodology is under development still, the need for an
evidence-based overview of available methodology, endorsement
of accepted methods, and guidelines for recommended methods
has become evident. In response to this, a Patient-Centered Out-
comes Research Institute (PCORI) has been created in the USA
to support research that can produce answers generated with the
use of rigorous, valid, patient-centered methods (Washington and
Lipstein, 2011; Gabriel and Normand, 2012). The PCOR Insti-
tute has adopted the following mission statement to guide their
work: “. . . help people make informed healthcare decisions, and
improves healthcare delivery and outcomes, by producing and pro-
moting high-integrity, evidence-based information that comes from
research guided by patients, caregivers, and the broader healthcare
community”(Washington and Lipstein, 2011). Further, developing
and improving the science and methods of comparative clin-
ical effectiveness research and producing high methodological
standards for research are among the current tasks the institute
is working on. A recently released draft of recommendations
for selected standards for the conduct of research leading to
evidence-based, patient-centered health interventions has been
reported (www.pcori.org). The report describes the rationale
behind creating standards for patient centeredness, for priori-
tizing topics for research, for choosing a study design, and for
designing, conducting, and reporting patient-centered outcomes
research (Gabriel and Normand, 2012). Clearly, a new“movement”
has come of age in terms of research agenda and priority. Patient-
centered outcomes research will have a focus that ranges from
the individual patient and help patients make informed decisions,
but will also focus on dissemination of knowledge, alleviate dis-
parities and focus on improvement of health systems in a broader
sense. Truly it makes sense to include patient-centered information
for improved patient-centered care. But, the tools for doing this
are not yet widely standardized nor implemented across ongoing
clinical investigations.
DEFINITIONS AND CONCEPTS OF PATIENT-CENTERED
OUTCOMES RESEARCH
A much discussed and debated definition; “health” is not the mere
absence of disease, but moreover “health” refers to the state of
human physical, social, and emotional well-being. Further, “qual-
ity of life” (QoL) may be viewed as any aspect of health, life
satisfaction, or happiness. Then, “health-related QoL” is a mul-
tidimensional assessment of health. In this figure (Figure 1) of
overlapping definitions, a “patient-reported outcome measure”
(PROM) may refer to a self-report (by the patient) of one or more
aspects of health. As is given, a PROM may be derived from any
of the health assessment fields, but may be much more narrow
focused, such as typically a focus on pain as a PROM, or a cluster
FIGURE 1 | Relation between measures of interest.
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of symptoms to define a specific domain, or the“symptom burden”
(Cleeland, 2007; Jeffery et al., 2009).
Consequently, three main approaches to the measurement of
PROMs in patients with cancer may be considered (Hadi et al.,
2010), as depicted in Figure 2. First, the generic approach to
health status measurement allows for the comparison across health
conditions; secondly, the cancer-generic modules which are more
focused on dimensions relevant to people with cancer (Luckett,
2011) and which may allow comparison of scores across groups
with cancer (of different or similar origin); and, lastly, any add-on
modules which focus more on specific domains relative to the type
of cancer, i.e., colorectal cancer (Whistance et al., 2009) or, liver
metastasis from colorectal cancer (Blazeby et al., 2009). Also, one
may consider specific domain-related instruments (i.e., fatigue;
sexuality) within or beyond the disease-specific domains.
Independent of this, it is important that the patient outcome of
investigation comes directly from the patient (Fiscella et al., 2011),
without the filtration or interpretation of information or graded
response by an investigator or anyone else. PROMs can be investi-
gated in either generic terms (i.e., overall/global health evaluation)
or with regard to more disease-specific aspects (i.e., cancer-specific
measures).
STANDARDS FOR PROM RESEARCH
While there are several benefits and ways of investigating PROMs,
there are equally many pitfalls and failures to this type of research,
of which a few shall be further addressed. Among the benefits are
the ability to use PROMs for assessment of nature of disease or
treatment effects not amenable to other scores; the ability to obtain
the patients own perception, rather than the health professionals’
judgments (which may often deviate from the patient); PROMs
may give reliable prognostic info as demonstrated in several studies
(Montazeri, 2009); and inform economic analyses (Blazeby, 2010).
More specifically, PROMs may inform decision-making (Hughes
et al., 2012) to the benefits of surgery in settings where surgery
may compete with non-surgical alternatives, or in settings were
surgery may only pose a marginal benefit or even the potential for
harm (Avery et al., 2008; Blazeby, 2010).
Among the troubling areas in this field is the different use and
availability of tools (Whistance et al., 2009; Cleeland and Sloan,
2010; Colwell et al., 2010; Macefield et al., 2013) – in some areas
there may be a lack of standardized and validated instruments,
while in other areas there may be instruments designed for the
same or similar purpose (Luckett, 2011), which may compete and
even clutter the interpretation of results obtained across studies.
Further, the availability and validity of instruments has been a
problem, with no standards for translational processes from one
language to another. This has now been rectified to some extent by
proposals of standards among others by organizations, such as the
EORTC (Koller et al., 2007). Also, increasingly validation studies
are performed across cancer types (Blazeby et al., 2009). Yet, still,
when trying to compare studies there is considerable heterogeneity
according to the PROMs used, the frequency, content, and presen-
tation of feedback, and the training offered to medical teams for
using PROMs (Luckett et al., 2009). Further, trials varied in their
unit of randomization, outcome measures, control of contamina-
tion, monitoring of PROM use, and length of follow-up (Luckett
et al., 2009). Obviously, there is a need for future interventions to
ensure that PROM data are used to optimum effect and for trials
to control for contamination and monitor use of PROMs to link
this with outcomes.
PROMs IN SURGICAL CANCER CARE AND RESEARCH
One should recognize that QoL investigation and the use of
PROMs has different applications to patients with advanced
cancers compared to those undergoing curative treatment.
FIGURE 2 | Approaches to PROMs research – from generic to specific.
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Historically, QoL issues may have had a stronger focus in advanced
cancer care and palliative medicine (Cella, 1995; Bottomley et al.,
2005; Groenvold et al., 2006; Byrne et al., 2007; Abernethy et al.,
2010; Cella et al., 2011; Amdal et al., 2013), but is now gain-
ing importance in several fields for which curative surgery may
be the central point in the care bundle for patients with cancer
(Tan et al., 2012; Williamson et al., 2012a,b; Macefield et al., 2013;
Pusic et al., 2013; Winters et al., 2013). Patient satisfaction (as a
PROM) with hospital care is indeed independent of morbidity,
treatment type, and QOL outcomes (Avery et al., 2006) – empha-
sizing the fact that PROMs may capture feedback information to
providers not easily obtained through other metrics. In contrast
to other fields, one should recognize that surgery in itself may
have immediate and long-lasting effects on PROMs and corre-
spondingly HRQoL measures, both in generic terms and also for
disease-specific inventories.
In clinical terms, surgeons or the associated caregiver can use
the results of PROM instruments to track patients’ functional sta-
tus and QoL changes through treatment, or in the follow-up of a
given treatment (Morris, 2006). Obtaining formalized and “objec-
tive” results (although based on the patients “subjective” report)
might help surgeons and physicians to better communicate with
patients during their treatment, especially with regard to patients’
expectations. Knowing that numerous clinical variables of uncer-
tain value are regularly followed after cancer surgery such as for
colorectal cancer (Kørner et al., 2005; Søreide et al., 2012), it is
troublesome to know that validated PROM/QoL instruments have
been put to use only rarely in the clinical setting.
A recent review (Macefield et al., 2013), found six systematic
reviews reporting on the evaluation of PROM in colon or rectal
cancer, two on esophageal cancer, and one on upper-GI cancers
in general (esophagogastric and pancreatobiliary). The authors
found that the systematic reviews found several limitations in
PROM reporting, heterogeneity in the use of PROMs (which ham-
pered comparison between studies) and overall very few studies
(four of eight RCTs on colorectal cancer; two of two trials on
esophageal cancer) were of satisfactory quality to draw somewhat
robust conclusions.
FUTURE DIRECTIONS
Patient-reported outcome measures research has proved to be
highly wanted for current modern research on clinical outcomes.
It is thus important that this be performed in a standardized and
proper manner. Standardizations and suggestions to improve this
is currently underway. The Task Force of The International Soci-
ety of QoL Research is working on a CONSORT extension for
reporting PROMs in randomized controlled trials (Calvert et al.,
2011) which may inform and structure the standards for using
health-related QoL in RCTS as either a primary or secondary out-
come (Brundage et al., 2012). As may be a problem across several
types of research, problems with proper sample size calculations
have been tangible in PROMs research as well. A recent review
have quantified the outcomes which should form the basis for
more reliable sample size calculation in the future (Cocks et al.,
2011), but still a major problem may be the agreement on type
of PROM, the measured (or reported) effect and the size in the
difference in measurements for making clinically useful interpre-
tations. Obviously, education on the user level is mandatory, as
is ensuring the agreement on proper timing for PROM assess-
ment (Ediebah et al., 2013). Compliance remains an issue in this
kind of research as in many other fields (Land et al., 2007), and
better understanding of drop-out rates and tools to potentially
improve compliance and reduce drop-outs is needed. Last but not
least, the proper analyses of obtained data, including pre-study
preparation of methodology and dealing with missing data. Also,
recommended methods (Macefield et al., 2013) of communicat-
ing patient-reported outcome and clinical data to patients (e.g., by
means of visually displayed outcomes or distributions) should be
followed so as to gain as widely clinical use of the obtained info
for each and every patient as possible.
Clearly, PROMs should be a prioritized area of current clin-
ical research not only in the palliative setting but more so for
patients receiving surgical care of curative intent for cancer. Sur-
geons’ ability to interpret and apply PROMs and QoL results
will surely improve with practice, and has an unreleased poten-
tial to contribute to a better understanding of the patients’
well-being.
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